A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma

Southwest Oncology Group Protocol S9911

Oliver W. Press, Joseph M. Unger, Rita M. Braziel, David G. Maloney, Thomas P Miller, Michael LeBlanc, Ellen R. Gaynor, Saul E. Rivkin, Richard I. Fisher

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial (S9911) of a novel regimen consisting of 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I 131 tositumomab (anti-CD20 antibody) in 90 eligible patients with previously untreated, advanced stage follicular lymphoma. Treatment was well tolerated. Reversible myelosuppression was the main adverse event and was more severe during CHOP chemotherapy than following radioimmunotherapy. The overall response rate to the entire treatment regimen was 90%, including 67% complete remissions (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs). Twenty-seven (57%) of the 47 fully evaluable patients who achieved less than a CR with CHOP improved their remission status after tositumomab/iodine I 131 tositumomab. With a median follow-up of 2.3 years, the 2-year progression-free survival (PFS) was estimated to be 81%, with a 2-year overall survival of 97%. This study has established the feasibility, tolerability, and efficacy of this regimen for patients with advanced follicular lymphoma. This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016).

Original languageEnglish (US)
Pages (from-to)1606-1612
Number of pages7
JournalBlood
Volume102
Issue number5
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Follicular Lymphoma
Oncology
Chemotherapy
Iodine
Non-Hodgkin's Lymphoma
Drug Therapy
Radiotherapy
Vincristine
Prednisone
Radioimmunotherapy
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Anti-Idiotypic Antibodies
Therapeutics
Antibodies
Survival
iodine-131 anti-B1 antibody

ASJC Scopus subject areas

  • Hematology

Cite this

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S9911. / Press, Oliver W.; Unger, Joseph M.; Braziel, Rita M.; Maloney, David G.; Miller, Thomas P; LeBlanc, Michael; Gaynor, Ellen R.; Rivkin, Saul E.; Fisher, Richard I.

In: Blood, Vol. 102, No. 5, 01.09.2003, p. 1606-1612.

Research output: Contribution to journalArticle

Press, Oliver W. ; Unger, Joseph M. ; Braziel, Rita M. ; Maloney, David G. ; Miller, Thomas P ; LeBlanc, Michael ; Gaynor, Ellen R. ; Rivkin, Saul E. ; Fisher, Richard I. / A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S9911. In: Blood. 2003 ; Vol. 102, No. 5. pp. 1606-1612.
@article{70d6460a1cff4d03bc38a228a0d92487,
title = "A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911",
abstract = "Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial (S9911) of a novel regimen consisting of 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I 131 tositumomab (anti-CD20 antibody) in 90 eligible patients with previously untreated, advanced stage follicular lymphoma. Treatment was well tolerated. Reversible myelosuppression was the main adverse event and was more severe during CHOP chemotherapy than following radioimmunotherapy. The overall response rate to the entire treatment regimen was 90{\%}, including 67{\%} complete remissions (CRs plus unconfirmed CRs [CRu's]) and 23{\%} partial remissions (PRs). Twenty-seven (57{\%}) of the 47 fully evaluable patients who achieved less than a CR with CHOP improved their remission status after tositumomab/iodine I 131 tositumomab. With a median follow-up of 2.3 years, the 2-year progression-free survival (PFS) was estimated to be 81{\%}, with a 2-year overall survival of 97{\%}. This study has established the feasibility, tolerability, and efficacy of this regimen for patients with advanced follicular lymphoma. This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016).",
author = "Press, {Oliver W.} and Unger, {Joseph M.} and Braziel, {Rita M.} and Maloney, {David G.} and Miller, {Thomas P} and Michael LeBlanc and Gaynor, {Ellen R.} and Rivkin, {Saul E.} and Fisher, {Richard I.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1182/blood-2003-01-0287",
language = "English (US)",
volume = "102",
pages = "1606--1612",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma

T2 - Southwest Oncology Group Protocol S9911

AU - Press, Oliver W.

AU - Unger, Joseph M.

AU - Braziel, Rita M.

AU - Maloney, David G.

AU - Miller, Thomas P

AU - LeBlanc, Michael

AU - Gaynor, Ellen R.

AU - Rivkin, Saul E.

AU - Fisher, Richard I.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial (S9911) of a novel regimen consisting of 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I 131 tositumomab (anti-CD20 antibody) in 90 eligible patients with previously untreated, advanced stage follicular lymphoma. Treatment was well tolerated. Reversible myelosuppression was the main adverse event and was more severe during CHOP chemotherapy than following radioimmunotherapy. The overall response rate to the entire treatment regimen was 90%, including 67% complete remissions (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs). Twenty-seven (57%) of the 47 fully evaluable patients who achieved less than a CR with CHOP improved their remission status after tositumomab/iodine I 131 tositumomab. With a median follow-up of 2.3 years, the 2-year progression-free survival (PFS) was estimated to be 81%, with a 2-year overall survival of 97%. This study has established the feasibility, tolerability, and efficacy of this regimen for patients with advanced follicular lymphoma. This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016).

AB - Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial (S9911) of a novel regimen consisting of 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I 131 tositumomab (anti-CD20 antibody) in 90 eligible patients with previously untreated, advanced stage follicular lymphoma. Treatment was well tolerated. Reversible myelosuppression was the main adverse event and was more severe during CHOP chemotherapy than following radioimmunotherapy. The overall response rate to the entire treatment regimen was 90%, including 67% complete remissions (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs). Twenty-seven (57%) of the 47 fully evaluable patients who achieved less than a CR with CHOP improved their remission status after tositumomab/iodine I 131 tositumomab. With a median follow-up of 2.3 years, the 2-year progression-free survival (PFS) was estimated to be 81%, with a 2-year overall survival of 97%. This study has established the feasibility, tolerability, and efficacy of this regimen for patients with advanced follicular lymphoma. This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016).

UR - http://www.scopus.com/inward/record.url?scp=0041440084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041440084&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-01-0287

DO - 10.1182/blood-2003-01-0287

M3 - Article

VL - 102

SP - 1606

EP - 1612

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -